Patients with Gal-3 levels above established thresholds (e.g., >17.8 ng/mL, >25.9 ng/mL, or above the median/75th percentile of the study population) exhibit substantially higher rates of death, recurrent myocardial infarction, hospitalization for HF, and the development of post-infarction HF compared to those with lower levels (Asleh et al., 2019; Tian et al., 2020; Kokturk et al., 2023). The gene discussed is LGALS3; the disease is myocardial infarction.